纤维蛋白溶解剂的临床应用。

The clinical use of fibrinolytic agents.

作者信息

Porter J M, Goodnight S H

出版信息

Am J Surg. 1977 Aug;134(2):217-21. doi: 10.1016/0002-9610(77)90348-8.

Abstract

Two fibrinolytic drugs, streptokinase and urokinase, have undergone extensive clinical evaluation in the past fifteen years. Current evidence suggests that these agents may become the drugs of choice in the treatment of certain patients with venous thrombosis and pulmonary embolism. The ultimate usefulness of fibrinolytic therapy in the treatment of thrombotic conditions other than venous thrombosis and pulmonary embolism has not yet been determined.

摘要

在过去的十五年中，两种纤溶药物，即链激酶和尿激酶，已经接受了广泛的临床评估。目前的证据表明，这些药物可能会成为某些静脉血栓形成和肺栓塞患者治疗的首选药物。纤溶疗法在治疗除静脉血栓形成和肺栓塞以外的血栓性疾病中的最终效用尚未确定。